Home  »  Finance   »  Right Now May Be the Best Buy-In Window for CymaBa...

Right Now May Be the Best Buy-In Window for CymaBay Therapeutics Inc. (CBAY)

CymaBay Therapeutics Inc. (CBAY) is priced at $6.95 after the most recent trading session. At the very opening of the session, the stock price was $6.59 and reached a high price of $6.75, prior to closing the session it reached the value of $6.68. The stock touched a low price of $6.35.Recently in News on January 8, 2023, CymaBay Therapeutics Announces Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis. Advances strategy to partner seladelpar for PBC outside U.S. You can read further details here

CymaBay Therapeutics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $7.14 on 01/20/23, with the lowest value was $5.67 for the same time period, recorded on 01/04/23.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

CymaBay Therapeutics Inc. (CBAY) full year performance was 116.88%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, CymaBay Therapeutics Inc. shares are logging -1.56% during the 52-week period from high price, and 316.14% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.67 and $7.06.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1201101 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the CymaBay Therapeutics Inc. (CBAY) recorded performance in the market was 6.54%, having the revenues showcasing 97.05% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 534.40M, as it employees total of 60 workers.

Analysts verdict on CymaBay Therapeutics Inc. (CBAY)

During the last month, 8 analysts gave the CymaBay Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 4.09, with a change in the price was noted +3.20. In a similar fashion, CymaBay Therapeutics Inc. posted a movement of +82.90% for the period of last 100 days, recording 594,717 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CBAY is recording 1.43 at the time of this writing. In addition, long term Debt to Equity ratio is set at 1.43.

CymaBay Therapeutics Inc. (CBAY): Technical Analysis

Raw Stochastic average of CymaBay Therapeutics Inc. in the period of last 50 days is set at 97.99%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 96.89%. In the last 20 days, the company’s Stochastic %K was 89.32% and its Stochastic %D was recorded 89.10%.

Let’s take a glance in the erstwhile performances of CymaBay Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 6.54%. Additionally, trading for the stock in the period of the last six months notably improved by 98.22%, alongside a boost of 116.88% for the period of the last 12 months. The shares increased approximately by 11.33% in the 7-day charts and went down by 44.59% in the period of the last 30 days. Common stock shares were driven by 97.05% during last recorded quarter.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts